Exosomes as biomarker-diagnostics and therapeutics for multiple sclerosis: promise, pitfalls, and the rising role of milk-derived exosomes, towards next-generation precision medicine
5 affiliations
- 1Department of Basic and Clinical Sciences, Medical School, University of Nicosia, UNIC Athens
- 2Immunogenetics Laboratory, 1 Department of Neurology, School of Medicine, Aeginition University Hospital, National and Kapodistrian University of Athens
- 3Laboratory of Genetics, Department of Biotechnology, School of Applied Biology and Biotechnology, Agricultural University of Athens
- 4United Nations Educational, Scientific and Cultural Organization (UNESCO) Chair on Adolescent Health Care, University Research Institute of Maternal and Child Health and Precision Medicine, National and Kapodistrian University of Athens and Hellenic Pasteur Institute
- 5Multiple Sclerosis and Demyelinating Diseases Unit, Center of Expertise for Rare Demyelinating and Autoinflammatory CNS Diseases (ERN-RITA), 1 Department of Neurology, School of Medicine, Aeginition University Hospital, National and Kapodistrian University of Athens
Abstract
Multiple sclerosis (MS) is a chronic, immune-mediated demyelinating disease of the central nervous system (CNS) characterized by inflammation, neurodegeneration, and failed remyelination. Extracellular vesicles (EVs), including exosomes, mediate intercellular communication by shuttling proteins, lipids, and nucleic acids. In MS, EVs participate in antigen presentation, blood–brain barrier (BBB) dysfunction, and neuron–glia crosstalk; their molecular cargo can reflect the cellular state of origin, making them attractive candidates as minimally invasive biomarkers. Parallel advances suggest EVs as promising drug-delivery vehicles capable of targeting the CNS. Mesenchymal stem cell (MSC)-derived exosomes have emerged as particularly promising, suppressing pro-inflammatory microglia, promoting oligodendrocyte maturation, and supporting remyelination in preclinical models. In the broader landscape of neurodegenerative diseases, exosomes exhibit a complex bidirectional regulatory role, serving both as pathological carriers facilitating the transcellular propagation of toxic proteins and as endogenous regulatory systems delivering anti-inflammatory factors and neurotrophic molecules. Among EV sources, milk-derived exosomes (MDEs) are abundant, orally bioavailable, stable in the gastrointestinal tract, and increasingly shown to cross biological barriers and modulate immunity—features that warrant serious consideration for MS diagnostics and therapeutics. Here, we summarize state-of-the-art evidence on the roles of EVs in MS pathobiology, candidate diagnostic signatures, and therapeutic strategies encompassing tolerogenic, anti-inflammatory, and remyelinating approaches. We review MDEs in depth: their composition, isolation rigor, manufacturability from dairy streams, biodistribution, and engineering for CNS targeting. We conclude with a translational roadmap and a critical appraisal of outstanding challenges in standardization, specificity, safety, and regulation, towards next-generation precision medicine in MS.
Related
- Deciphering the gut-liver axis in MASLD: from dysbiosis-driven pathogenesis to precision microbiome therapeutics
- Targeting IL-2 to inflamed tissues via oxidation-specific epitopes enables third-generation bispecific IL-2 therapeutics
- TA-TMA as a clinical model for precision complement therapeutics in stem cell transplantation
- Decoding molecular heterogeneity in lupus nephritis: integrating single-cell and spatial multi-omics for endotype-driven precision therapeutics
- Personalized cancer vaccines: bridging immune-oncology and precision medicine for advanced therapeutics
BibTeX
@article{skarlis2026exosomes,
title = {{Exosomes as biomarker-diagnostics and therapeutics for multiple sclerosis: promise, pitfalls, and the rising role of milk-derived exosomes, towards next-generation precision medicine}},
author = {Charalampos Skarlis and Myrto Lantzi and Eleni Papakonstantinou and George P. Chrousos and Dimitrios Vlachakis and Maria Anagnostouli},
journal = {Frontiers in Immunology},
year = {2026},
month = nov,
doi = {10.3389/fimmu.2026.1880349},
url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.1880349/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Exosomes as biomarker-diagnostics and therapeutics for multiple sclerosis: promise, pitfalls, and the rising role of milk-derived exosomes, towards next-generation precision medicine
AU - Charalampos Skarlis
AU - Myrto Lantzi
AU - Eleni Papakonstantinou
AU - George P. Chrousos
AU - Dimitrios Vlachakis
AU - Maria Anagnostouli
PY - 2026
DA - 2026/11/10
JO - Frontiers in Immunology
DO - 10.3389/fimmu.2026.1880349
UR - https://www.frontiersin.org/articles/10.3389/fimmu.2026.1880349/full
AB - Multiple sclerosis (MS) is a chronic, immune-mediated demyelinating disease of the central nervous system (CNS) characterized by inflammation, neurodegeneration, and failed remyelination. Extracellular vesicles (EVs), including exosomes, mediate intercellular communication by shuttling proteins, lipids, and nucleic acids. In MS, EVs participate in antigen presentation, blood–brain barrier (BBB) dysfunction, and neuron–glia crosstalk; their molecular cargo can reflect the cellular state of origin, making them attractive candidates as minimally invasive biomarkers. Parallel advances suggest EVs as promising drug-delivery vehicles capable of targeting the CNS. Mesenchymal stem cell (MSC)-derived exosomes have emerged as particularly promising, suppressing pro-inflammatory microglia, promoting oligodendrocyte maturation, and supporting remyelination in preclinical models. In the broader landscape of neurodegenerative diseases, exosomes exhibit a complex bidirectional regulatory role, serving both as pathological carriers facilitating the transcellular propagation of toxic proteins and as endogenous regulatory systems delivering anti-inflammatory factors and neurotrophic molecules. Among EV sources, milk-derived exosomes (MDEs) are abundant, orally bioavailable, stable in the gastrointestinal tract, and increasingly shown to cross biological barriers and modulate immunity—features that warrant serious consideration for MS diagnostics and therapeutics. Here, we summarize state-of-the-art evidence on the roles of EVs in MS pathobiology, candidate diagnostic signatures, and therapeutic strategies encompassing tolerogenic, anti-inflammatory, and remyelinating approaches. We review MDEs in depth: their composition, isolation rigor, manufacturability from dairy streams, biodistribution, and engineering for CNS targeting. We conclude with a translational roadmap and a critical appraisal of outstanding challenges in standardization, specificity, safety, and regulation, towards next-generation precision medicine in MS.
SN - 1664-3224
ER -